Current Opinion in Pulmonary Medicine

Article	Citations
Sarcoidosis epidemiology: recent estimates of incidence, prevalence and risk factors	84
Endotypes and phenotypes in obstructive sleep apnea	67
Pulmonary pathology of COVID-19: a review of autopsy studies	44
Coal mining and lung disease in the 21st century	40
Chronic obstructive pulmonary disease and COVID-19: interrelationships	40
Climate change and respiratory diseases: a 2020 perspective	36
Transmission of respiratory tract infections at mass gathering events	33
Editorial: The explosive epidemic outbreak of novel coronavirus disease 2019 (COVID-19) and the persistent threat of respiratory tract infectious diseases to global health security	32
ABCA3 mutations in adult pulmonary fibrosis patients: a case series and review of literature	31
Viral respiratory infections: a cause of community-acquired pneumonia or a predisposing factor?	30
Recent advances in rheumatoid arthritis-associated interstitial lung disease	29
A clinical review of long-COVID with a focus on the respiratory system	25
Household air pollution in India and respiratory diseases: current status and future directions	24
COVID-19: vaccines, efficacy and effects on variants	24
MicroRNAs: future biomarkers and targets of therapy in asthma?	24
Small airway disease in chronic obstructive pulmonary disease: insights and implications for the clinician	20
Drug-induced sarcoidosis-like reactions	20
Adherence to Global Initiative for Chronic Obstructive Lung Disease guidelines in the real world: current understanding, barriers, and solutions	20
Obstructive sleep apnea and cancer: a complex relationship	20
New guidelines for severe community-acquired pneumonia	19
Update in adult community-acquired pneumonia: key points from the new American Thoracic Society/Infectious Diseases Society of America 2019 guideline	18
Occupational lung diseases in the 21st century: the changing landscape and future challenges	18
Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world – opportunities and challenges	17
Genetics in sarcoidosis	17
A contemporary review of radiation pneumonitis	17

Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies	17
Socioeconomic determinants and disparities in sarcoidosis	17
TBX4 variants and pulmonary diseases: getting out of the ‘Box’	16
Asthma and severe acute respiratory syndrome coronavirus 2019: current evidence and knowledge gaps	16
Upper airway muscles: influence on obstructive sleep apnoea pathophysiology and pharmacological and technical treatment options	16
Monitoring early stage lung disease in cystic fibrosis	16
Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment	16
The role of computed tomography scan in the diagnosis of COVID-19 pneumonia	15
The impact of fungal allergic sensitization on asthma	15
ICU preparedness in pandemics: lessons learned from the coronavirus disease-2019 outbreak	15
An update on sarcoidosis-associated pulmonary hypertension	15
Sarcoidosis and autoimmunity	14
Telehealth and virtual health monitoring in cystic fibrosis	14
COVID-19: a new burden of respiratory disease among South African miners?	14
Risk stratification of indeterminate pulmonary nodules	14
Obstructive sleep apnea in pulmonary fibrosis	14
Diabetes, insulin resistance, and asthma: a review of potential links	14
Advances in the epidemiology, clinical features, diagnosis, clinical management and prevention of coronavirus disease 2019	13
The other connective tissue disease-associated interstitial lung diseases: Sjogren's syndrome, mixed connective tissue disease, and systemic lupus erythematosus	13
Yoga and Tai Chi: a mind–body approach in managing respiratory symptoms in obstructive lung diseases	13
COVID-19 and other respiratory tract infections at mass gathering religious and sporting events	13
Opioids and sleep	13
Pleuroparenchymal fibroelastosis	13
Insights into pathogenesis and clinical implications in myositis-associated interstitial lung diseases	13
Nontuberculous mycobacteria in cystic fibrosis	12
COVID-19 outcomes in people with cystic fibrosis	12
Does gender matter: sex-specific aspects of symptoms, outcome, and therapy of obstructive sleep apnea	12
Impact of obesity on pulmonary function: current understanding and knowledge gaps	12
Pneumococcal virulence factors in community-acquired pneumonia	12
COVID-19 new diagnostics development: novel detection methods for SARS-CoV-2 infection and considerations for their translation to routine use	11
Recent advances in sarcoidosis genomics: epigenetics, gene expression, and gene by environment (G × E) interaction studies	11
Asthma–COPD overlap: review of diagnosis and management	11
SMART - is it practical in the United States?	11
The current understanding and future directions for sputum microbiome profiling in chronic obstructive pulmonary disease	11
New pharmacologic agents for insomnia and hypersomnia	11
Treatment of pulmonary exacerbations in cystic fibrosis	11
Revisiting matrix metalloproteinase 12: its role in pathophysiology of asthma and related pulmonary diseases	11
Severe pulmonary toxicity associated with inhalation of pyrethroid-based domestic insecticides (Bop/Sapolio): a case series and literature review	11
Critical care of patients with pulmonary arterial hypertension	10
Atypical mycobacterial infections – management and when to treat	10
Pulmonary rehabilitation in a postcoronavirus disease 2019 world: feasibility, challenges, and solutions	10
Advances in molecular diagnostic tests for pneumonia	10
The evolving role of radiological imaging in cystic fibrosis	10
Update on sarcoidosis guidelines	10
Robotic bronchoscopy and future directions of interventional pulmonology	10
Respiratory and sleep-related complications of multiple system atrophy	10
Role of antioxidants in the treatment of gastroesophageal reflux disease-associated idiopathic pulmonary fibrosis	10
Drug treatment of COVID-19 infection	10
Unprecedented: the toxic synergism of Covid-19 and climate change	10
Advancing bacteriophages as a treatment of antibiotic-resistant bacterial pulmonary infections	10

Implementation of digital home monitoring and management of respiratory disease	10
Looking into the future of sarcoidosis: what is next for treatment?	10
Pneumonitis associated with immune checkpoint inhibitors among patients with non-small cell lung cancer	9
The role of PET in the management of sarcoidosis	9
Human global and population-specific genetic susceptibility to Mycobacterium tuberculosis infection and disease	9
Pulmonary adverse events following immune checkpoint inhibitors	9
Vaping epidemic in US teens: problem and solutions	9
At a crossroads: coronavirus disease 2019 recovery and the risk of pulmonary vascular disease	9
Epidemiology and real-life experience in progressive pulmonary fibrosis	9
Immunology of sarcoidosis: old companions, new relationships	9
Current practices in the management of central airway obstruction	9
Burden of idiopathic pulmonary fibrosis on patients’ emotional well being and quality of life: a literature review	9
Robotic bronchoscopy for peripheral pulmonary lesions: a convergence of technologies	9
Drug-resistant tuberculosis: advances in diagnosis and management	9
Rapid eye movement predominant obstructive sleep apnoea: prognostic relevance and clinical approach	9
Obstructive lung diseases and allergic bronchopulmonary aspergillosis	9
Telehealth in chronic obstructive pulmonary disease: before, during, and after the coronavirus disease 2019 pandemic	9
Beyond antibiotics for pulmonary nontuberculous mycobacterial disease	8
Alternative algorithms and devices in sleep apnoea diagnosis: what we know and what we expect	8
Pulmonary hypertension in majority countries: opportunities amidst challenges	8
Hit-hard and early versus step-up treatment in severe sarcoidosis	8
Frailty in patients with interstitial lung disease	8
Beta-blockers in chronic obstructive pulmonary disease: the good, the bad and the ugly	8
Biopsy in interstitial lung disease: specific diagnosis and the identification of the progressive fibrotic phenotype	8
COVID-19 – pathogenesis and immunological findings across the clinical manifestation spectrum	8
Noninvasive positive pressure ventilation in stable patients with COPD	8
Lethal zoonotic coronavirus infections of humans – comparative phylogenetics, epidemiology, transmission, and clinical features of coronavirus disease 2019, The Middle East respiratory syndrome and se	8
Bronchoscopic diagnosis of peripheral lung lesions	8
Influenza: clinical aspects, diagnosis, and treatment	8
Drug-induced sleep endoscopy: techniques, interpretation and implications	7
Sexual and reproductive health in cystic fibrosis	7
Lung microbiome, gut–lung axis and chronic obstructive pulmonary disease	7
How low should we go? Potential benefits and ramifications of the pulmonary hypertension hemodynamic definitions proposed by the 6th World Symposium	7
New pharmacologic agents for obstructive sleep apnoea: what do we know and what can we expect?	7
Glymphatic MRI techniques in sleep and neurodegenerative diseases	7
COVID-19 infection in patients with sarcoidosis: susceptibility and clinical outcomes	7
Experimental models of sarcoidosis: where are we now?	7
Revealing the pathogenic and ageing-related mechanisms of the enigmatic idiopathic pulmonary fibrosis (and chronic obstructive pulmonary disease)	7
Pathogenesis of fibrosis in interstitial lung disease	7
Oxygen for interstitial lung diseases	7
Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: advances in patient and lesion selection	7
Advanced pulmonary sarcoidosis	7
Strategies for prediction of drug-resistant pathogens and empiric antibiotic selection in community-acquired pneumonia	7
The justification for the progressive fibrotic phenotype	7
Chronic obstructive pulmonary disease risk assessment tools: is one better than the others?	7
Lung cancer staging, the established role of bronchoscopy	6
Recent advances in the management of systemic sclerosis-associated interstitial lung disease	6
Asthma guidelines: comparison of the National Heart, Lung, and Blood Institute Expert Panel Report 4 with Global Initiative for Asthma 2021	6
Pharmacogenetics of antitumor necrosis factor therapy in severe sarcoidosis	6
Sarcoidosis associated pulmonary hypertension: an update	6
Sarcoidosis and maligancy: the chicken and the egg?	6
Therapeutic pipeline for individuals with cystic fibrosis with mutations nonresponsive to current cystic fibrosis transmembrane conductance regulator modulators	6
Pulmonary toxicity associated with occupational and environmental exposure to pesticides and herbicides	6
The progressive fibrotic phenotype in current clinical practice	6
Emerging clinical perspectives in cystic fibrosis liver disease	6
Pulmonary arterial hypertension: closing the gap in congenital heart disease	6
Management of pneumothorax: an update	6
Home monitoring in asthma: towards digital twins	6
Managing chronic rhinosinusitis in severe asthma	6
Sleep medicine and coronavirus disease 2019	6
New biomarkers for respiratory infections	6
Drug-induced comorbidities in patients with sarcoidosis	6
Changing landscape: psychological care in the era of cystic fibrosis transmembrane conductance regulator modulators	6
Cyclic alternating patterns and arousals: what is relevant in obstructive sleep apnea? In Memoriam Mario Giovanni Terzano	6
Care of the postcoronavirus disease 2019 patient	6
Evolving spectrum of treatment for CTEPH	5
Occupational exposures and sarcoidosis: current understanding and knowledge gaps	5
Management of malignant pleural effusions	5
Molecular profiling in sarcoidosis	5
Unclassifiable, or simply unclassified interstitial lung disease?	5
Eosinophils in chronic obstructive pulmonary disease: are they just another biomarker?	5
Current treatment of sarcoidosis	5
Host-directed therapies for COVID-19	5
Pulmonary rehabilitation in interstitial lung diseases	5
Progress and challenges in fungal lung disease in cystic fibrosis	5
Management of immunosuppressants in the era of coronavirus disease-2019	5
Advances in lung transplantation for interstitial lung diseases	5
Transbronchial lung cryobiopsy for the diagnosis of interstitial lung diseases	5
Clinical trials in group 3 pulmonary hypertension	5
Advances in development of new tuberculosis vaccines	5

Ageing with Interstitial lung disease: preserving health and well being	4
Methamphetamine-associated pulmonary arterial hypertension	4
Allergen bronchoprovocation test: an important research tool supporting precision medicine	4
What's new in endobronchial ultrasound for mediastinal staging?	4
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: DIPNECH	4
Telehealth and its implementation in respiratory sleep medicine	4
Pediatric sarcoidosis with diagnostic and therapeutical insights	4
Home monitoring of coronavirus disease 2019 patients in different phases of disease	4
Transbronchial biopsy vs. bronchoalveolar lavage in interstitial lung disease	4
Management of patients with idiopathic pulmonary fibrosis and lung cancer: challenges in clinical practice	4
The influence of age and sex in sarcoidosis	4
Influenza management with new therapies	4
Environmental and occupational exposures in interstitial lung disease	4
Silica-associated lung disease in developing countries	4
More than sleepiness: prevalence and relevance of nonclassical symptoms of obstructive sleep apnea	4
The different facets of sickle cell disease-related pulmonary hypertension	4
Respiratory viral infections in the immunocompromised	4
Percutaneous tracheostomy in the ICU: a review of the literature and recent updates	4
Pulmonary hypertension in interstitial lung disease and in chronic obstructive pulmonary disease: different entities?	4
Airborne transmission of respiratory viruses including severe acute respiratory syndrome coronavirus 2	4
Disease-specific gaps within fungal respiratory tract infections: clinical features, diagnosis, and management in critically ill patients	4
Postpulmonary embolism syndrome	4
Diagnostic and therapeutic challenges of chronic obstructive pulmonary disease in the elderly	4
Telemedicine and adherence monitoring in children with asthma	4
Obstructive lung diseases burden and COVID-19 in developing countries: a perspective	4
How might endotyping guide chronic obstructive pulmonary disease treatment? Current understanding, knowledge gaps and future research needs	3
Precision medicine in chronic obstructive pulmonary disease: how far have we come?	3
Pre-chronic obstructive pulmonary disease: a pathophysiologic process or an opinion term?	3
Ageing and chronic obstructive pulmonary disease: interrelationships	3
Nutritional and metabolic management for cystic fibrosis in a post-cystic fibrosis transmembrane conductance modulator era	3
Update on balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension	3
The treatment of sarcoidosis: translating the European respiratory guidelines into clinical practice	3
Emerging phenotypes of pulmonary hypertension associated with COPD: a field guide	3
Editorial: Coronavirus disease 2019 (COVID-19) – advances in epidemiology, diagnostics, treatments, host-directed therapies, pathogenesis, vaccines, and ongoing challenges	3
Coronavirus disease 2019 management	3
Personalized medicine in sarcoidosis: unravelling biomarkers for targeted care	3
The emerging role of inorganic elements as potential antigens in sarcoidosis	3
Chronic hypersensitivity pneumonitis: real world diagnostic criteria	3
Military deployment-related respiratory problems: an update	3
Sleep in the intensive care unit	3
Thoracic computed tomography in the progressive fibrotic phenotype	3